Adam wrote sheepishly in his 4/27/2012 blog that, "The regulatory bar for blood-based cancer drugs has been set very low after FDA's Oncology Drugs Advisory Committee in March recommended approval for Talon Therapeutics'(TLON_) Marqibo. If that drug can get a positive vote, carfilzomib should be a lock."
That's like throwing in the towel on TLON, knowing FDA will approve Marqibo, imo.
Considering, Adam is the self proclaimed "biotech guru", who has nothing but a BS in political science from Emory University. I don't see how he can enlighten us about anything, except make money for his masters by posting innuendoes and bashing stocks.